Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1W90B)

Drug Name

PF-07209960 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-15 (IL15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[2]
AMG-714	DM1T3KQ	Coeliac disease	DA95	Phase 2	[3]
SAR445877	DM91KZL	Aggressive cancer	2A00-2F9Z	Phase 2	[4]
N-803	DM4ZN8M	Human immunodeficiency virus infection	1C62	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
3	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
4	Clinical pipeline report, company report or official report of Sanofi
5	The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.